0
0
Read Time:9 Minute, 22 Second
The RWE Oncology Market is expected to grow at a CAGR of 14.2% from 2022–2029 to reach $1.65 billion by 2029. The growth of this market is driven by factors such as the rising prevalence of cancer, rapidly growing big data in healthcare, the shift from volume to value-based care, and the rising focus on personalized healthcare. Furthermore, emerging markets, rising focus on end-to-end RWE services, and rising adoption of mobile applications and wearable devices and AI in RWE are expected to provide significant growth opportunities for market players and new entrants.
Here are the top 10 companies operating in the RWE Oncology Market
Founded in 2004 and headquartered in Indiana, U.S., Anthem is engaged in delivering health benefit solutions through a broad portfolio of integrated healthcare plans and related services, along with a wide range of specialty products such as life and disability insurance benefits, dental, vision, behavioral health benefit services, as well as long-term care insurance and flexible spending accounts. HealthCore, Inc., Anthem’s wholly-owned health outcomes research subsidiary, operates its business for life science companies, government & academia, and payers & providers in the global RWE oncology solutions market.
The company has a geographical presence across the U.S. and serves more than 107 million people through its affiliated companies. The company conducts its business through its subsidiaries in over 25 states across the U.S. Some of the company’s subsidiaries are AIM Specialty Health (U.S.), Aspire Health (U.S.), and Beacon Health Options, Inc. (U.S.).
IQVIA Holdings Inc. (U.S.)
Founded in 1982 and headquartered in North Carolina, U.S., IQVIA provides advanced analytics, technology solutions, and contract research services to the life sciences industry. The three business segments through which the company operates are Technology & Analytics, Research & Development, and Contract Sales & Medical Solutions. The technology & analytics solutions segment provides critical information, technology, and real-world solutions and services to life sciences clients, providing access to deep clinical data in oncology, rare disease, and other specialty areas.
IQVIA’s strong presence in the market is attributed to various factors such as its service capabilities, diversified service offerings, and its ability to enhance the penetration of its offerings. IQVIA has a strong geographical presence through its 262 offices across 82 countries, including the U.S., Japan, Germany, France, Spain, and Italy.
Incorporated in 1990 and headquartered in Dublin, Ireland, ICON provides consulting, clinical development, and commercialization services to pharmaceutical, biotechnology, medical devices companies, and government and public health organizations. The group specializes in strategic development, management, analysis, and programs that support all clinical development stages, from compound selection to Phase I–IV clinical studies. The company’s offerings include clinical research, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real-world intelligence, and site & patient solutions. The company provides services such as Real World Evidence Strategy & Analytics, Real World Evidence and Late Phase Research, and Direct-to-Patient Support through its real-world intelligence offering.
The company has a geographical presence across 41 countries, including Ireland, Australia, Japan, Russia, China, India, Canada, U.S., Mexico, Brazil, Peru, Argentina, South Africa, Italy, Germany, France, U.K., Turkey, Sweden, and Spain.
PPD Inc. (U.S.)
Founded in 1985 and headquartered in North Carolina, U.S., PPD provides integrated drug development, laboratory, and management lifecycle services to the biopharmaceutical industry. The company provides real-world evidence solutions through its peri and post-approval services subsegment (a part of the clinical development services segment). The company’s clinical development services segment assists in advancing drug development programs and designing protocols for post-approval and real-world patient observation, leading to new ideas and products. The company offers RWE services to pharmaceutical, biotech, and medical devices companies and academic, government, and public health organizations. The company’s real-world evidence services include hematology/oncology and chronic conditions, immuno-oncology, cell and gene therapy, biomarkers, and rare diseases.
The company has a geographical presence across the U.K., the U.S., Bulgaria, Philippines, Mexico, Australia, China, and India and operates in the global RWE oncology solutions market through its subsidiary Evidera (U.S.).
Founded in 2008 and headquartered in Burton, U.K., Clinigen Group is engaged in providing medicines. The company operates in two business segments, namely, Products and Services. The services segment offers real-world evidence solutions and services to capture anonymized data to gain unique insights into how patients are diagnosed and treated in a real-world setting. The company has a strong geographical presence through sales, offices, and warehouses across the U.S, the U.K., Japan, Australia, New Zealand, South Africa, Belgium, Germany, France, and Switzerland.
Meticulous Research in its latest publication on RWE Oncology Market has predicted the growth of 14.2% during the forecast year 2022-2029.
Cognizant Technology Solutions Corporation (U.S.)
Founded in 1994 and headquartered in New Jersey, U.S., Cognizant Technology provides IT services such as digital business, digital operations, and digital systems & technology. The company offers digital services and solutions, consulting, application development, systems integration, application testing, application maintenance, infrastructure, business process, and healthcare services. The four reportable segments of Cognizant are Financial Services; Products and Resources; Healthcare; and Communications, Media, And Technology. The company provides real-world evidence solutions through its Healthcare segment.
With offices and operations in more than 85 cities, the company has a geographical presence across the U.S., the Philippines, Canada, Mexico, India, Australia, China, Japan, Singapore, Thailand, South Africa, Germany, the U.K., France, Italy, Spain, Sweden, Switzerland, the Netherlands, and Poland.
Founded in 1977 and headquartered in California, U.S., Oracle provides products and services that address all aspects of corporate information technology (IT) environments—applications, platforms, and infrastructure. The company operates through three business segments, namely, Cloud License, Hardware, and Services. The services segment provides solutions to the global RWE oncology solutions market to maximize their investments in Oracle applications, platforms, and infrastructure technologies. Oracle Health Sciences software offers real-world evidence solutions for clinical data managers, biostatisticians, and data scientists.
The company has a strong geographical presence across India, the U.S., Canada, Mexico, Argentina, Brazil, Peru, and Australia. Some of the company’s subsidiaries are Oracle Software Technology GmbH (Switzerland), Oracle Global Partners (Ireland), OCAPAC Holding Company UC (Ireland), OCAPAC research Partner UC (Ireland), Oracle EMEA Holdings Limited (Ireland), Oracle International Group Limited (Isle of Man), Oracle EMEA & CAPAC Holdings Limited (Bermuda), and Oracle International Holdings Limited (Bermuda).
Parexel International Corporation (U.S.)
Incorporated in 1982 and headquartered in Massachusetts, U.S., Parexel is engaged in providing clinical research and logistics, medical communications, consulting, commercialization, and advanced technology products and services for pharmaceutical, biotechnology, and medical devices industries worldwide. The company provides clinical research, consulting, outsourcing services, medical communications, medical affairs, and real-world data sciences. The real-world data sciences segment provides services like business & strategy consulting, genomics / translational medicine, study optimization, patient & site recruitment and feasibility, patient safety/pharmacovigilance, real-world evidence generation, and market access planning.
The company has a geographical presence across the U.S., Mexico, Argentina, Brazil, Denmark, Czech Republic, Poland, the Netherlands, Belgium, Russia, Spain, France, Germany, U.K., Sweden, Switzerland, Australia, Korea, Singapore, India, Thailand, Indonesia, Japan, China, Malaysia, and the Middle East & Africa.
Founded in 1937 and headquartered in Massachusetts, U.S., PerkinElmer provides products, services, and solutions for the diagnostics, food, environmental, industrial, life sciences research, and laboratory services markets. Discovery & Analytical Solutions and Diagnostics are the two business segments through which the company operates in the global RWE oncology solutions market. The discovery & analytical solutions segment offers products and services for the end markets such as life sciences and applied markets, which comprises industrial, environmental, and food markets. The company offers real-world evidence solutions through its discovery & analytical solutions to the end market- life sciences.
The company has a strong geographical presence across the U.S., China, the U.K., Germany, India, Italy, France, Japan, and others and offers its products and services in more than 190 countries using its network of distributors to sell products in the regions where it does not have a sales and service presence. Some of the company’s subsidiaries are Clinical & Analytical Service Solutions Ltd. (U.K.), PerkinElmer SAS (France), PerkinElmer (India) Pte Ltd., PerkinElmer Srl (Italy), PerkinElmer Japan Co. Ltd. (Japan), and PerkinElmer Technologies GmbH & Co. KG (Germany).
SAS Institute Inc. (U.S.)
Founded in 1976 and headquartered in North Carolina, U.S., SAS Institute provides analytics, business intelligence, and data management software & services. The company serves its solutions in automotive, banking, capital markets, casinos, communication, healthcare, health insurance, life sciences, and other industry verticals. The company operates in the global RWE oncology solutions market by offering end-to-end capabilities in data management, cohort extraction, and advanced analytics to generate clinical and scientific evidence.
SAS has customers in 147 countries and has a strong geographical presence across the U.S., Canada, Latin America, Europe, Asia-Pacific, and the Middle East & Africa. Its software is installed at more than 83,000 business, government, and university sites.
UnitedHealth Group Incorporated (U.S.)
Incorporated in 1977 and headquartered in Minnesota, U.S., UnitedHealth Group is a diversified healthcare company with four reportable segments across two business platforms, namely, UnitedHealthcare (health benefits) and Optum (health services). The Optum segment has dedicated units that help improve overall health system performance by optimizing care quality, reducing costs, improving consumer experience and care provider performance, and leveraging distinctive capabilities in data and analytics, pharmacy care services, population health, healthcare delivery, and healthcare operations. Optum operates through Optum Health, Optum Insight, and Optum Rx business segments. The company’s Optum Insight segment provides real-world solutions.
The company offers services in more than 150 countries and has a strong geographical presence across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Flatiron Health, Inc. (U.S.)
Founded in 2012 and headquartered in New York, U.S., Flatiron Health, Inc. became an independent affiliate of the Roche Group in 2018. Flatiron Health is a healthcare technology and services company focused on accelerating cancer research and improving patient care. The company focuses on partnering with community cancer practices, major academic research centers, and top therapeutic oncology companies. Flatiron’s oncology care model network includes 55 community oncology practices across 20 states and 2.4 million active patient records.
The company works with over 280 community cancer centers and eight academic cancer centers in the U.S. The company has over 2,500 employees comprising software engineers, data scientists, biostatisticians, epidemiologists, health professionals, and other experts.
Authoritative Research on the RWE Oncology Market – Global Opportunity Analysis and Industry Forecast (2022-2029)
Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:
- Recent financial performance
- Key products
- Significant company strategies
- Partnerships and acquisitions
The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
